Alterations of Gut Microbiota in Patients With Graves' DiseaseOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared gut microbiota composition between 55 patients with Graves' disease, an autoimmune cause of hyperthyroidism, and 48 healthy controls.
How was it studied?
Fecal samples were analyzed by 16S rRNA gene sequencing. Investigators compared overall diversity, then used ordination methods and linear discriminant analysis effect size to identify taxa distinguishing the two groups, and correlated key taxa with clinical parameters.
What did they find?
Bacterial richness and diversity were similar between groups, but overall community composition differed significantly. Firmicutes decreased and Bacteroidetes increased in Graves' disease patients. Prevotellaceae, Veillonellaceae, and Prevotella_9 were associated with Graves' disease, while Lachnospiraceae, Ruminococcaceae, Faecalibacterium, Lachnospira, and Lachnospiraceae NK4A136 were associated with healthy controls. Of 22 significant taxa identified, 18 were increased and 4 decreased in patients. A discriminant model built from these taxa distinguished patients from controls with an AUC of 0.825.
Why it matters
A distinct gut microbiota signature reliably separated Graves' disease patients from healthy controls, supporting a possible role for gut bacteria in disease pathogenesis. The authors note further studies are needed to clarify this role.